NCT06067399 Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control
| NCT ID | NCT06067399 |
| Status | Recruiting |
| Phase | — |
| Sponsor | New Valley University |
| Condition | Type 2 Diabetes |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2025-12-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Diabetes mellitus (DM) is an epidemic disease, with approximately 463 million persons diagnosed with it. Of those, 90% are patients with type 2 DM (T2DM). Some estimates indicate that 700 million cases of DM will be reported in 2045. T2DM develops due to insulin resistance, leading to reduced insulin secretion. DM has a number of associated complications, such as nephropathy, neuropathy, and cardiovascular disease.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed to have Uncontrolled type 2 diabetes mellitus (HbA1C more than 7%) Exclusion Criteria: 1. Patients diagnosed to have type 1 diabetes. 2. Patients are diagnosed to have secondary diabetes. 3. Clinical states associated with increased RDW: * Anemia (Female Hb less than 12, Male Hb less than 13) either due to hemolysis, or in response to ineffective red cell production, which can be caused by deficiencies in iron, vitamin B12 or folate. * After blood transfusions * Pregnancy, thrombotic thrombocytopenic purpura and inflammatory bowel disease.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06067399 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06067399 currently recruiting?
Yes, NCT06067399 is actively recruiting participants. Contact the research team at asmaanady_1010@med.nvu.edu.eg for enrollment information.
Where is the NCT06067399 trial being conducted?
This trial is being conducted at Al Khārjah, Egypt.
Who is sponsoring the NCT06067399 clinical trial?
NCT06067399 is sponsored by New Valley University. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.